Lexicon Pharmaceuticals

Lexicon's revised Zynquista bid in type 1 diabetes faces lingering safety questions
First Word Pharma
Tue, 10/29/24 - 08:07 pm
Lexicon Pharmaceuticals
type 1 diabetes
Zynquista
FDA
Viatris makes good on CEO's dealmaking promise with $25M licensing pact for Lexicon's heart med Inpefa
Fierce Pharma
Thu, 10/17/24 - 08:18 pm
Viatris
Pharma CEOs
heart failure
Inpefa
Lexicon Pharmaceuticals
Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch
Fierce Pharma
Wed, 08/14/24 - 11:03 am
Lexicon Pharmaceuticals
type 1 diabetes
sotagliflozin
layoffs
restructuring
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Stock Titan
Fri, 06/21/24 - 11:15 am
Lexicon Pharmaceuticals
type 1 diabetes
FDA
sotagliflozin
Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Clinical Trials Arena
Fri, 11/17/23 - 11:29 am
Lexicon Pharmaceuticals
Inpefa
clinical trials
heart failure
AHA
Lexicon gets FDA approval for Inpefa to treat heart failure
Pharmaceutical Technology
Mon, 05/29/23 - 12:14 pm
Lexicon Pharmaceuticals
FDA
Inpefa
heart failure
Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate
Endpoints
Wed, 11/30/22 - 08:01 pm
Lexicon Pharmaceuticals
FDA
type 1 diabetes
sotagliflozin
Lexicon CEO touts ‘wonderful morning’ as diabetic pain drug clears phase 2, teeing up hopeful partnership talks
Fierce Biotech
Thu, 06/30/22 - 11:03 am
Lexicon Pharmaceuticals
diabetic neuropathy
diabetes
diabetic pain
clinical trials
LX9211
Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure
Endpoints
Tue, 05/31/22 - 11:58 pm
Lexicon Pharmaceuticals
sotagliflozin
heart failure
FDA
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals
Fierce Pharma
Mon, 04/4/22 - 10:59 am
Lexicon Pharmaceuticals
ACC
diabetes
sotagliflozin
type 2 diabetes
heart failure
3 Biotech Stocks That Jumped Last Week
Motley Fool
Sun, 01/17/21 - 04:54 pm
biotech
biotech stocks
Lexicon Pharmaceuticals
sotagliflozin
Nucana
Aldeyra Therapeutics
reproxalap
The biotech resurrection continues
EP Vantage
Fri, 01/15/21 - 10:39 am
biotech
Lexicon Pharmaceuticals
DBV Technologies
Pfizer
Trillium Therapeutics
AHA 2020 – sotagliflozin wins come too late for Lexicon
EP Vantage
Tue, 11/17/20 - 10:45 am
Lexicon Pharmaceuticals
sotagliflozin
AHA
heart failure
chronic kidney disease
Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline
Endpoints
Thu, 07/30/20 - 11:03 am
Lexicon Pharmaceuticals
Xermelo
R&D
TerSera Therapeutics
Lexicon Pharma shares plummet after FDA denies appeal against drug rejection
Reuters
Tue, 12/3/19 - 12:08 am
Lexicon Pharmaceuticals
FDA
type 1 diabetes
Zynquista
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Yahoo/Benzinga
Sun, 09/15/19 - 10:05 pm
Merck
Pifeltro
FDA
Delstrigo
Novo Nordisk
oral semaglutide
Kodiak Sciences
MeiraGTx Holdings
IPOs
Exagen
IGM Biosciences
Arrowhead Pharmaceuticals
Lexicon Pharmaceuticals
Bluebird Bio
vTv Therapeutics
Sanofi paying Lexicon $260M to exit diabetes alliance
BioPharma Dive
Wed, 09/11/19 - 12:51 pm
Sanofi
Lexicon Pharmaceuticals
diabetes
type 1 diabetes
Zynquista
Sanofi ends partnership with Lexicon after trial failure
In-Pharma Technologist
Mon, 08/5/19 - 10:45 pm
Sanofi
Lexicon Pharmaceuticals
clinical trials
Zynquista
diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sat, 07/27/19 - 01:58 pm
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
What's Next for Lexicon Pharmaceuticals?
Motley Fool
Mon, 03/25/19 - 10:21 pm
Lexicon Pharmaceuticals
sotagliflozin
Zynquista
Sanofi
diabetes

Pages